Le Lézard
Classified in: Health
Subjects: NPT, RCL

Consumer Foodborne Illness Advocacy Group Reacts to USDA Announcement


STOP Foodborne Illness Applauds USDA for Tackling Salmonella in Poultry, Creating a Safer Food Supply

CHICAGO, Aug. 3, 2022 /PRNewswire/ -- The U.S. Department of Agriculture's (USDA) Food Safety and Inspection Service (FSIS) announced groundbreaking plans to declare Salmonella an adulterant.

In addition, the USDA has plans to establish enforceable raw poultry product standards. These include a uniform final product standard for all poultry products, requiring Salmonella testing for poultry flocks entering facilities, and discussing a zero-tolerance policy in an effort to prevent contaminated products from reaching consumers.

Salmonella remains a leading cause of foodborne illness in the US with an estimated 1.35 million cases of salmonellosis annually resulting in 420 deaths.

Stop Foodborne Illness (STOP; www.stopfoodborneillness.org) ? a national non-profit representing consumers impacted by food safety failures and collaborates with academia, the food industry, and government to prevent foodborne illnesses ? applauds the USDA-FSIS commitment to tackle the significant burden of illness caused by Salmonella in poultry.

"STOP supports meaningful and enforceable Salmonella product standards that determine which products can safely enter the market and those which cannot. We, along with consumers, have been petitioning the agency for these modern advancements, along with our colleagues from the Coalition for New Poultry Safety Program," says Mitzi Baum, CEO of STOP.

Chicken and turkey are major contributors to Salmonella sicknesses ? according to the US Centers for Disease Control and Prevention. "Until today's announcement, Salmonella standards haven't been meaningfully updated for over 25 years, even though science has advanced dramatically," adds Baum.

STOP recognizes the amount of work that needs to be done to get the new standards right. "Deputy Under Secretary Eskin's plan to set enforceable standards limiting Salmonella in poultry is a historic step toward a safer food supply," said former FSIS administrator and STOP board member, Michael Taylor. "This is an initiative that I hope consumers and industry support." 

About Stop Foodborne Illness (STOP): STOP is a 28-year-old non-profit that collaborates with partners in academia, the food industry, and government to prevent foodborne illnesses. We advocate for effective food safety policies and facilitate culture change to increase food safety.

Media Contact:
Ruth Wyatt
219-771-9842
[email protected]

SOURCE Stop Foodborne Illness


These press releases may also interest you

at 06:25
Genexine (KOSDAQ: 095700), a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of serious unmet medical needs, announced a merger with EPD Biotherapeutics...

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...



News published on and distributed by: